Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,299.60
(
0.69%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.60
(
-0.05%
)
Bitcoin
74,200.55
(
0.35%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 57874

Wednesday, 01/23/2008 12:25:37 PM

Wednesday, January 23, 2008 12:25:37 PM

Post# of 257253
Bad timing... or astute dealmaking?

Yesterday, Teva paid $400M to acquire CoGenesys (#msg-26163282), the HGSI spin-off that owns the rights to the albumin-fusion technology used in Albuferon.

Today, HGSI reveals a safety issue with Albuferon and HGSI shares plunge 45%.

Q: Was Teva blindsided by the Albuferon problem… or did Teva know about it and use it to negotiate a lower acquisition price?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now